Key result
Oral rizatriptan exhibits linear pharmacokinetics with ~40% bioavailability in males across standard doses.
Why the study?
What are the pharmacokinetics, dose proportionality, and tolerability of single oral doses of rizatriptan in healthy volunteers?
RCT (n=24)
randomized crossover
No
What are the pharmacokinetics, dose proportionality, and tolerability of single oral doses of rizatriptan in healthy volunteers?
Single oral doses of rizatriptan exhibit slightly greater plasma concentrations in women but linear pharmacokinetics within standard clinical dose ranges for both genders.
Answers are grounded in this paper and cite their sources.
Supports predictable dosing in standard ranges; extends pharmacokinetic data for rizatriptan modeling and trials.
AIMS: The pharmacokinetics and dose proportionality of rizatriptan single oral doses from 2.5 to 15 mg administered as solutions to healthy volunteers were studied. METHODS: In a randomized, crossover study with four periods, twenty-four healthy volunteers (12 males and 12 females) took single oral doses of 2.5, 5, 10, and 15 mg rizatriptan in Periods 1-4. In a fifth period, subjects received 4 mg intravenous (i.v.) rizatriptan as a reference. Plasma and urine rizatriptan concentrations were determined at several timepoints/intervals for 12 and 24 h, respectively. RESULTS: The arithmetic mean AUC values following single oral doses of 2.5, 5, 10, and 15-mg rizatriptan were 16, 33, 72, and 127 ng ml-1 h, respectively, in males; and 19, 42, 97, and 161 ng ml-1 h, respectively, in females. The overall bioavailability (F ) of rizatriptan was approximately 40% in males. Following the 4 mg reference i.v. dose, the apparent plasma clearance (CL) and renal clearance (CLr ) were 1042 and 225 ml min-1, respectively, in males; and 821 and 174 ml min-1, respectively, in females. CONCLUSIONS: The disposition kinetics of oral rizatriptan were linear for doses of 2. 5-10 mg in males, and for doses of 2.5-5 mg in females. However, the degree of nonlinearity for higher doses was minor for both genders. The plasma concentrations of rizatriptan were slightly greater in women compared to men but the difference was not considered to be clinically meaningful. Also, the clearance of rizatriptan appeared to be mainly nonrenal.
No takes yet. Share an insight, caveat, or question.
Lee et al. (1999) conducted an RCT in Healthy volunteers (n=24). Rizatriptan vs. 4 mg intravenous rizatriptan (reference) was evaluated on Pharmacokinetics (AUC) and dose proportionality. The disposition kinetics of oral rizatriptan were linear for doses of 2.5- in males and 2.5- in females, with an overall bioavailability of approximately 40% in males.
Synapse has enriched 10 related papers. Consider them for comparative context: